New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

Today's Free Fly Stories
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all day >>
07:09 EDTIMGNSentiment towards ImmunoGen could rebound, says RBC Capital
Subscribe for More Information
07:09 EDTUPI, VSCIUroplasty and Vision Sciences to merge to become Cogentix Medical
Uroplasty (UPI) and Vision-Sciences (VSCI) entered into a definitive merger agreement under which the two companies will combine in an all-stock transaction to create a new company expected to generate revenue of approximately $50M for the fiscal year beginning April 1, 2015. Under the terms of the agreement, which was unanimously approved by the boards of both companies, each outstanding share of Uroplasty's common stock will be exchanged for 3.6331 shares of Vision-Sciences' common stock. Upon completion of the merger, Uroplasty shareholders will own 62.5% of the shares of the combined company on a fully-diluted basis, and Vision-Sciences shareholders will own 37.5%. Following the closing of the transaction, which is expected to occur during the first half of 2015, the combined company will conduct business as Cogentix Medical (CGNT). The combined company will have its U.S. headquarters in Minnetonka, MN, where Uroplasty's current headquarters is located. Cogentix Medical will be led by Rob Kill, who will become President and Chief Executive Officer; Brett Reynolds, who will become Chief Financial Officer; and Darin Hammers, who will become Senior Vice President of Global Sales and Marketing. Cogentix Medical's board of directors will be comprised of the five representatives from Uroplasty's existing board and three representatives from Vision-Sciences' existing board.
07:08 EDTUPI, VSCIUroplasty, Vision Sciences to merge in all stock transaction
Subscribe for More Information
07:07 EDTESRX, ABBVExpress Scripts and AbbVie to expand access to Viekira Pak
Subscribe for More Information
07:07 EDTSCSSteelcase volatility elevated into Q3 and booking outlook
Steelcase January call option implied volatility is at 39, April is 31, May is at 30; compared to its 26-week average of 32 according to Track Data, suggesting larger near term price movement into the expected release of Q3 on December 23.
07:06 EDTUPI, VSCIUroplasty, Vision Sciences to merge in all stock transaction
Subscribe for More Information
07:05 EDTIRMDiRadimed resumes domestic distribution of infusion pumps
Subscribe for More Information
07:05 EDTMAINMain Street announces new portfolio investment totaling $45M
Main Street announced that it recently led a new portfolio investment totaling $45M of invested capital to facilitate the purchase of the assets of Garlock Rubber Technologies, a division of a subsidiary of EnPro Industries, with Main Street funding $29.8M of the investment. Main Street's portion of the investment in GRT included $16.7M of first lien, senior secured term debt and a $13.1 million equity investment for a control equity ownership position in the Company. Main Street and its co-investor partnered with the Company's management team to facilitate the transaction.
07:04 EDTANVAllied Nevada Gold initiated with a Buy at H.C. Wainwright
Subscribe for More Information
07:04 EDTARMKARAMARK upgraded at RBC Capital
Subscribe for More Information
07:04 EDTAUXLXobi's Xiapex receives positive opinion by CHMP
Swedish Orphan Biovitrum AB and partner Auxilium announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for the use of Xiapex for the treatment of adult men with Peyronie's disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. The use of Xiapex in men with Peyronie's disease is supported by positive safety and efficacy outcome data from two double-blind placebo-controlled studies IMPRESS I and II.
07:03 EDTKTOSKratos Defense awarded $72.3M award from AFSAT program office
Subscribe for More Information
07:02 EDTCGCarlyle Group and Warburg Pincus to acquire DBRS
Subscribe for More Information
07:02 EDTHGSHChina HGS receives local government's subsidies for Liangzhou project
China HGS Real Estate announced that the company received government's subsidies in the amount of approximately $1.73M for its Shanty Area Reform Project surrounding Liang Zhou Road located in Hantai District, Hanzhong City. As a key part of China's urbanization process, the Shanty Area Reform Project is an important public project designed to promote the integration of urban and rural areas, improve the quality of urbanization and facilitate sustained and healthy economic development.
07:01 EDTSYNSynthetic Biologics reports positive topline results from SYN-004 Phase 1a trial
Subscribe for More Information
07:01 EDTPRAHPRA Health initiated with an Outperform at William Blair
Subscribe for More Information
07:01 EDTSWIRSierra Wireless to acquire Maingate for $90M in cash
Sierra Wireless announced that it has entered into a definitive agreement to acquire Maingate for $90M in cash. The transaction is expected to close in February 2015. Sierra Wireless will acquire all the outstanding shares of Maingate, including those held by Nordic private equity fund Verdane Capital VI, and retain the company’s M2M business which includes wireless connectivity services for M2M. Maingate’s current shareholders will retain the Enterprise Solutions business, which provides real-time data management tailored for energy services. CIBC World Markets Inc. is acting as financial advisor, and Blake Cassels & Graydon LLP and Advokatfirman Delphi are acting as legal counsel, to Sierra Wireless. Jefferies International Limited is acting as financial advisor and Advokatfirman Vinge KB is acting as legal counsel for Maingate.
06:59 EDTATROAstronics sees FY15 revenue $655M-$695M, consensus $666.39M
Subscribe for More Information
06:58 EDTATROAstronics announces test systems odrer
Subscribe for More Information
06:57 EDTTASRTASER initiated with an Outperform at Oppenheimer
Target $28.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | all day >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use